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Abstract
Background—International guidelines recommend the use of appropriate informed consent
procedures in low literacy research settings because written information is not known to guarantee
comprehension of study information.
Objectives—This study developed and evaluated a multimedia informed consent tool for people
with low literacy in an area where a malaria treatment trial was being planned in The Gambia.
Methods—We developed the informed consent document of the malaria treatment trial into a
multimedia tool integrating video, animations and audio narrations in three major Gambian
languages. Acceptability and ease of use of the multimedia tool were assessed using quantitative
and qualitative methods. In two separate visits, the participants’ comprehension of the study
information was measured by using a validated digitised audio questionnaire.
Results—The majority of participants (70%) reported that the multimedia tool was clear and
easy to understand. Participants had high scores on the domains of adverse events/risk, voluntary
participation, study procedures while lowest scores were recorded on the question items on
randomisation. The differences in mean scores for participants’ ‘recall’ and ‘understanding’
between first and second visits were statistically significant (F (1,41)=25.38, p<0.00001 and (F (1,
41) = 31.61, p<0.00001 respectively.
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Conclusions—Our locally developed multimedia tool was acceptable and easy to administer
among low literacy participants in The Gambia. It also proved to be effective in delivering and
sustaining comprehension of study information across a diverse group of participants. Additional
research is needed to compare the tool to the traditional consent interview, both in The Gambia
and in other sub-Saharan settings.
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Introduction
Informed consent is a practical application of respect for person which is a fundamental
principle of research [1]. The process of informed consent is meant to ensure that the
decision to participate in clinical research is freely made after an individual has received,
considered and understood fully the complete study information without being coerced,
induced, unduly influenced or intimidated [2]. For informed consent to fulfil its goals
researchers must not only provide full disclosure of study information but they must also
ensure full comprehension of the information to potential study participants. Informed
consent must be provided in the languages and terminologies understandable to the
participants to allow him/her understand the study information to make an informed decision
on whether or not to participate [2,3].
Comprehensive systematic reviews [4,5] of clinical research conducted in sub-Sahara Africa
showed that participants often demonstrated poor comprehension of various domains of
informed consent. For example, only 10% of mothers of study children in The Gambia [6]
and 20% of Ghanaian women [7] demonstrated good comprehension of the concept of
placebo. Similarly, participants from Ivory Coast [8], Nigeria [9], Senegal [10], Kenya [11],
Uganda [12] and Ethiopia [13] had sub-optimal comprehension of voluntary participation,
autonomy, risks/benefits, randomisation and blinding. These unacceptably low levels of
comprehension may be due to a combination of factors. These include poor communication
between the participants and the persons administering the consent (e.g. due lack of time and
power imbalance making the participants not to ask necessary questions).
Furthermore, central to this problem is the almost exclusive reliance on written information
document in research settings where many study participants are unable to read and
understand documents written either in foreign or local languages [5,14,15]. In such
situations, the World Medical Association Declaration of Helsinki recommends the use of
appropriate alternative informed consent procedures that will engender adequate
comprehension of the study information [16,17].
Nishimura et al. [18] in a recently published systematic review identified several effective
strategies for improving informed consent process including enhanced consent forms,
extended discussions and multimedia. Enhanced consent form involved the use of simplified
paper consent document with revised layout, text styling, and sometimes with added
pictures. In extended discussion, a study team member engaged participants in additional
discussions and, multimedia approach involved presentation of study information through
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combined use of video, audio and animations [19]. A meta-analysis showed a modest but
statistically non-significant increase in comprehension scores of participants randomised to a
multimedia-based consent approach when compared to their counterparts randomised to
control consent approach (Standardised Mean Difference [SMD]=0.30, 95% CI, −0.23 to
0.84). Similar comparison of enhanced consent form and extended discussion with control
consent increased the comprehension scores significantly (SMD 1.73, 95% CI, 0.99 to 2.47;
SMD 0.53, 95% CI, 0.21 to 0.84 respectively [18]. These findings raise concerns about the
impact of multimedia in informed consent process, although, previous studies reported its
usefulness in promoting retention of consent information longer than one week [20,21].
An earlier review by Flory and Emanuel [19] also showed that multimedia tools are not
significantly effective in aiding participants’ comprehension. This submission agreed with
the conclusions of a Cochrane review [22] that ‘the empirical literature is not yet sufficiently
developed to draw definitive conclusions about the general effectiveness of or value derived
from multimedia consent tools’. Nevertheless, critics argue that the reported limited
usefulness of multimedia tool is untenable because the effectiveness of multimedia consent
approach was evaluated in studies with considerable methodological flaws. For example,
some of the studies had no standard controls, and in others, informed consent documents
were merely presented on computer screens for participants to read [18]. Apart from these,
the studies included in the systematic reviews [18,19,22] were conducted in developed
countries where literacy rates were high. Consequently, the conclusions of lack of
effectiveness of multimedia approach may not be applicable to low literacy populations in
sub-Saharan Africa. Although no study from sub-Saharan Africa is yet to report the potential
usefulness of multimedia for delivering study information during informed consent process;
media-based technology is becoming cheaper to implement, readily available and more
manageable in Africa [18,23]. Thus, assessing the effectiveness of a multimedia informed
consent tool for improving the consenting process is becoming increasingly crucial in low
literacy research settings in Africa.
As a first step, we describe here how we developed and pilot-tested a multimedia tool to
provide information for a clinical trial scheduled to take place among low and non-literate
participants in The Gambia. This study was also aimed at gathering preliminary data to
determine the effectiveness of a locally designed multimedia tool in aiding informed consent
comprehension of participants in the low literacy research community.
Materials and Methods
The PRINOGAM Trial
The development of the multimedia tool was done using the informed consent document for
PRINOGAM trial (ClinicalTrials. gov NCT01838902). Briefly, PRINOGAM is an open-
label, four-arm treatment trial, aimed at determining the lowest possible primaquine dose to
obtain a substantial gametocytocidal effect in asymptomatic malaria infected individuals, as
this may reduce the risk of harmful effects in Glucose-6-Phosphate Dehydrogenase (G6PD)
deficiency.
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The trial was planned to take place concurrently at Basse and Jahaly areas of The Gambia
where level of literacy of the inhabitants is low. The Gambia is one of the smallest West
African countries with a population of 1.79 million people and adult literacy rate of less than
30% [24]. Mandinka, Fula and Wolof are three major ethno-linguistically distinct groups
populating the study areas. In previous studies [6,25] conducted in Gambian communities,
the local ethic committees recommended that oral interpretations of the English version of
written informed consent documents should be provided to potential participants by trained
field staff who are native speakers of the local languages [26]. This is because, in addition to
low literacy rate, no written translation of consent documents to local languages is possible
as no standardised written format for the local languages exist [25,27]. Because most
participants are not literate, they gave consent by thumb-printing the consent form in the
presence of an impartial witness.
This pilot study of the multimedia consent tool was conducted among healthy volunteers in
Basse, an area which shares similar epidemiologic and demographic features with Jahaly.
Development of multimedia tool from informed consent document of PRINOGAM
We worked with a multimedia expert who had extensive training and experience in motion
graphics and interactive media design to develop the participant information document of
PRINOGAM trial. The information document was earlier written by the Principal
Investigator of the trial with technical support from the Medical Research Council (MRC)
Clinical Trials Support Manager who ensured that all relevant information was adequately
and comprehensibly presented in the document. The document were submitted along with
the study protocol to an independent body of scientists who reviewed and confirmed that
information contained in the document was satisfactory to engender informed decision-
making by potential study participants. The information document was further submitted to
the local ethical committee who also reviewed and approved the document as conforming to
internationally agreed ethical requirements for conduct of clinical trials.
The approved information document contained 11 sections namely: introduction, reason for
the study, what is G6PD, how to take part, what would happen if one took part in the study,
what blood tests would be done, what are the side effects and possible risks of taking part,
potential benefits, would taking part in this study be kept confidential, who has reviewed this
study, who can be contacted if one has questions? The messages in each section were
graphically translated into a context-specific visual story. We serially reviewed these
storyboards to confirm appropriateness to Gambia research setting. The stories were acted in
role-plays by members of the clinical trial team after undergoing several training and
rehearsals. The final role-play on each section of information sheet was serially video-
recorded by the multimedia expert.
Three experienced linguistic professionals who are native speakers of the three major
Gambian languages and are also familiar with clinical research concepts were contracted to
audio-translate each section of the participant information document. The audio-translations
were confirmed to be consistent with the English version by another three native speakers of
the languages. The audio-translations were recorded as voice-over on the video-recorded
role-plays by the multimedia expert. Sections which could not be visually conveyed in the
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role-plays e.g symptoms of adverse events of study drugs like headache, diarrhoea, passage
of dark-coloured urine were graphically represented with animations.
Review of multimedia tool
The first draft of the multimedia tool in a Digital Video Disc (DVD) was given to two
qualified lay persons and two experienced researchers to confirm whether the contents of the
tool was consistent with the contents of the participant information document of
PRINOGAM trial. They all agreed that the tool included all essential information on the
study as requested by ethical and Good Clinical Practice (GCP) guidelines, and that it used
dialects that were well understandable to general populace. In very few areas, one of the
narrators wrongly used a local language ‘biir bumuti’ which means ‘lower abdominal pain’
to describe ‘abdominal pain’ as one of the adverse effects of the investigational products.
This was corrected with appropriate word ‘nahl bumuti’. Also, omission of ‘hel butey’
meaning ‘nausea’ was discovered and this was included in the revised version. Non-
inclusion of dark coloured urine as a major complication of G6PD deficiency was pointed
out by one of the researchers and this was included in the revised version.
Pilot-testing
A purposive sample of 42 healthy male and female volunteers aged 18-49 years was
recruited to pilot-test the multimedia informed consent tool. The upper limit of the age range
(49 years) was based on data from previous studies [28,29]. The lower age limit (18 years)
was chosen to avoid the logistical challenges associated with obtaining informed consent
from under-aged participants. Participants were recruited from the north and south parts of
Basse to ensure representation. Despite being representative of the PRINOGAM trial
population and participants could in the future become eligible, they were not screened for
PRINOGAM when the pilot-testing was carried out. After obtaining a written informed
consent, we played the multimedia tool on a laptop computer for each participant in his/her
preferred local language in noise-free consulting rooms at MRC facilities located within
Basse Major Health Centre. The participants were requested to ask questions if they were
not clear about the contents of the multimedia tool.
To assess acceptability and ease of use of the multimedia tool, an 8-item questionnaire was
adapted from a similar study conducted in South Africa [30]. The original questionnaire
contained 15 question items on acceptability and ease of use of an alternative informed
consent tool. The relevant part of the question items were retained e.g. “do you like the
pictures in the tool” while non-relevant questions were removed e.g “do you know how to
replace the battery of the tool”. After watching the multimedia video and participants
confirmed they had no questions, the 8-item questionnaire was administered to each
participant to assess acceptability and ease of use of multimedia tool. Participants responded
by indicating either ‘yes’ or ‘no’ to each question item. Following the questionnaire
administration, we assessed the participants’ comprehension using a Digitised Audio
Informed Consent Comprehension Questionnaire (DICCQ) that was previously validated in
low literacy Gambian populations. The development and psychometric evaluation of
DICCQ has been described elsewhere [31]. Briefly, DICCQ is a 26-item questionnaire
consisting of a combination of closed-ended, multiple choice and open-ended question
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items. Psychometric evaluation of DICCQ done in urban and rural Gambian populations
showed that the questionnaire was reliable and valid [31]. The question items in DICCQ are
consistent with the elements of informed consent required to ensure understanding of
potential participants according to international ethical guidelines [2,32]. The following
domains of informed consent are covered in the DICCQ: voluntary participation (Q1), rights
of withdrawal (Q2,8,11,15), study procedures (Q17, 18,21,22), study purpose (Q16,20),
blinding (Q3,4), confidentiality(Q5), compensation (Q9,14), randomization (Q10,23),
autonomy (Q13), meaning of giving consent (Q12), benefits (Q19), risks/adverse effects
(Q25), therapeutic misconception (Q24), placebo (Q26). The question items in DICCQ are
listed in Table 4.
We further assessed acceptability and ease of use of DICCQ using the questionnaire adapted
from the South African study described above [30].
To assess how much of the study information was retained, the participants were recalled
one week after first administration and the digitised comprehension questionnaire was re-
administered to the participants.
Focus group discussions
During the second visit, selected participants were invited for Focus Group Discussions
(FGD) to further explore acceptability and ease of use of multimedia consent tool and
digitised informed consent comprehension questionnaire. A separate group of six men and
women were invited for the FGD sessions. Participants were segregated by sex to ensure
homogeneity and open discussions in each group. A purpose-designed FGD guide was used
and the first author, MOA, served as the facilitator of the discussions. The proceedings were
audio-taped after verbal consent was obtained from the participants. These were transcribed
into English texts by two independent native speakers. We identified the main themes of the
transcribed texts and content analysis of these themes was performed.
Ethical consideration
Ethical approvals were obtained from the ethics committees of London School of Hygiene
and Tropical Medicine, UK and Gambia Government/Medical Research Council Joint
Ethics Committee. Due to absence of standardised writing formats for Gambian languages
and high illiteracy rates, informed consent was obtained from the participants in this study
by trained field assistants who were native speakers of the local languages. The trained
assistants provided oral interpretations of the study information to the participants in the
local languages he/she understood. After the potential participants had agreed to join the
study, literate participants (about 10% in this study) signed the consent form while the
majority (about 90%) thumb-printed the consent form in the presence of an impartial
witness. Participation was voluntary and confidential.
Scoring system—The scoring system used in previous validation work of DICCQ [31]
was applied:
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Closed ended question items in the first section Each correct answer was scored 3; wrong answer was scored 0 and
responses with ‘I don’t know’ were scored 1
Open-ended question items which are follow-
up questions to the closed ended question items
in the first section
Each correct answer was scored 5, partially correct answer was
scored 3, incorrect answer was scored 0, while ‘I don’t know’
responses were scored 1
In the second section, participants chose ONE
correct answer out of FOUR option responses
Each correct answer was scored 3, incorrect answer was scored 0 or
‘I don’t know’ responses were scored 1
In the third section, participants chose more
than one correct answers from FOUR option
responses
Full correct answers were scored 4, partially correct answers were
scored 2, wrong answers were scored 0 and ‘I don’t know’ answers
were scored 1
In the fourth section, participants responded
using their own words to open-ended question
items
Full correct answer was scored 5, partially correct answers were
scored 3, wrong answers were scored 0 and ‘I don’t know’
responses were scored 1
Data analysis
Data on acceptability and ease of use of multimedia tool and digitised questionnaire were
entered on Microsoft Excel while data on participant comprehension were retrieved from the
in-built database within DICCQ and exported into Microsoft Excel. Acceptability and ease
of use were assessed by calculating the percentage of ‘yes’ responses indicated by
participants on the questionnaire. Mean participants’ scores (and standard deviations) on
DICCQ were calculated to determine the domains of informed consent which were most or
least understood by the participants.
Further analysis was done by adopting the definition of comprehension used by Minnies et
al. [33] which consists of two components: recall and understanding. ‘Recall’ was defined as
correct answers to the close-ended and multiple choice questions while ‘understanding’ was
correct responses given to the open-ended questions [33].
Repeated measures analysis of variance model was done to determine the effect of the
multimedia and the effect of time on the participants’ recall and understanding scores at the
two study visits. Pair-wise comparison of the mean difference of participants’ scores
between first and second visits was performed and appropriate Bonferroni corrections were
made to allow for multiple comparisons. Analysis was done with Stata version 12.1 (College
Station, USA) with p<0.05 (two-tailed) considered significant.
Results
Forty-two participants consisting of 20 females and 22 males were recruited. Table 1 shows
socio-demographic characteristics of the study participants. The median age was 34.5 ± 11;
(range, 18-48 years), 90% were Mandinka and less than 10% had Western education. Each
playing session of the multimedia tool lasted an average of 20 minutes, while questionnaire
administration through DICCQ took an average of 32 minutes.
All participants liked the features of the multimedia tool, would like to use it again, and
wanted future study information delivered using the tool (Table 2). About 70% reported that
they were comfortable with the tool and that it was easy to follow. However, about 10% of
participants suggested changes to the Fula translation of the tool. The dialect (Fula Puta)
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used in the tool was not generally acceptable to the participants. Fula Torah was suggested
as the appropriate dialect.
The colour, pictures and voices used in the DICCQ were acceptable to the participants
(Table 3). About 60% reported it was easy to follow and 70% were comfortable with it.
About 17% suggested changes to the tool mainly on reducing administration time (8%) and
waiting time (9%).
Table 4 shows that the mean participants’ scores were high on the question items on adverse
event/risk (4.36 ± 1.21), voluntary participation (2.86 ± 0.65), meaning of giving consent
(2.93 ± 0.46), study procedures (3.33 ± 0.95) while lowest mean scores were recorded on the
two question items about randomisation (0.02 ± 0.15) and (0.88 ± 1.13).
The differences in the mean scores for participants’ recall between first and second visits
were statistically significant [F (1,41)=25.38, p<0.00001] (Table 5). Similarly, the mean
scores for participants’ understanding between first and second visits were statistically
significant [F (1,41)=31.61, p<0.00001]. Pair-wise comparison of the significance levels for
the time difference of the participants’ recall scores at the two study visits showed a mean
time difference of 2.33, standard error of 0.463 and p<0.0001, 95% CI (1.398-3.269). The
participants’ understanding scores showed a mean time difference of 3.60, standard error of
0.639 and p<0.0001, 95% CI (2.304-4.887).
Findings of FGDs
Acceptability
Overall, there is a consensus that the multimedia tool was clear, helpful, informative, easy to
follow and understand. Most of the participants were excited about watching the video and
hearing their local languages being used to explain the study information. One male
participant expressed that the tool was capable of improving understanding of study
information as follows: ‘I have been coming to this hospital for over 10 years; I have never
seen a thing like this. The sound is very good and clear to me, I am sure this thing will help
to improve understanding. I am happy (and) like to join (PRINOGAM) study’.
A female participant commented: ‘Though I have taken part in MRC studies before, but this
one will be different. The picture and the information are clear, I am very impressed. My
concern is if I get pregnant before the time this study starts, how will I take part?’
Ease of use
The majority of the participants admitted that they could not used a computer, but could use
mobile phones on daily basis, which they claimed made the multimedia and DICCQ tools
easy to follow and use. One of the participants noted: ‘I must thank you people for thinking
of this very nice thing. Although, I am not used to a computer, I can use mobile phones very
well. (So), I can follow and even use this computer easily’.
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Suggested changes to multimedia and DICCQ
One participant said: ‘The video is fine but it will be better if background music is reduced’.
A male participant suggested reducing the time to administer the DICCQ and reduction in
overall waiting time. ‘I am happy with this tool,’ he said, ‘but you have to do something
about the time (administration and waiting time), so that we can return quickly to our places
of work’.
Discussion
This study evaluated a multimedia tool developed to obtain informed consent from low
literacy participants who were potentially eligible to enrol in a clinical trial. Despite the fact
that only 10% of the study population had formal education, the computerised tool was well
received and easy to administer. Similarly, a digitised audio comprehension questionnaire
developed in a previous study [31] was also acceptable to these participants. The
participants expressed satisfaction with the tools and wanted future studies to adopt them.
However, they suggested reducing the administration time for the digitised questionnaire,
overall waiting time and background music in the multimedia.
The mean participants’ scores were relatively high on the question items about adverse
events/risk, voluntary participation, meaning of giving consent and study procedures,
implying that the participants understood these elements better. Conversely, the scores were
lowest on the items on randomisation showing that the participants had least understanding
on this domain. Illustrations of the study information using a combination of video,
animations and oral explanation in local languages could have contributed to the high
comprehension scores recorded by participants in this study. This finding represents a new
insight into the use of multimedia tool to deliver consent information to low literacy
participants in sub-Saharan Africa.
Furthermore, the multimedia tool increased significantly both recall and understanding
scores of the participants and this is consistent with the results from some previous studies
[34-38]. The increase in participants’ recall and understanding scores observed after one
week period could be explained by the quiz/feedback strategy adopted in the digitised
questionnaire. This introduced the possibility of enhancement or practice effect due to
memorisation which might occur when participants gave correct answers or when the
researchers clarified area of concerns. To minimise the memorisation or practice effect, the
digitised questionnaire used closed ended, multiple-choice and open-ended items which
were likely to elicit responses that truly reflect participants’ comprehension of the
information.
A major benefit of the multimedia tool is that it consistently provides the same research
information to all participants in the same manner. This strategy removes inter-person
variations in translations of informed consent information to the low literacy research
participants. This becomes crucial as a participant’s comprehension is influenced by the
communication skills of the person administering the consent. This is truer in contexts like
the Gambia, where there is no standard writing format for the local languages and the person
administering the consent plays a key role in translating it orally. It was therefore critical
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that we employed the services of experienced linguistic professionals who were native
speakers to translate the written English version of the informed consent document to the
audio forms of three major Gambian languages.
Furthermore, the development of the multimedia tool involved many technical processes
including graphical translation of elements of the informed consent document to appropriate
visual stories. These were further acted in role-plays by trained individuals before video,
animations and audio-translations in local languages are systematically added. Some
researchers have argued that the time and cost involved in the production of a multimedia
tool might further add to logistic challenges of the conduct of clinical trials [39,40].
However, the ultimate benefits of ensuring well-informed research participants through the
use of multimedia intervention could, in addition to improving participants’ comprehension,
protect their freedom to decide, and also potentially improve the quality of data and outcome
of the research. This remains a worthy venture even if it requires spending a little more than
expected.
The use of a multimedia tool to deliver study information during informed consent process
may weaken compassionate human interactions that form the basis of research ethics [41].
Therefore, it could be counter-productive to depend solely on the technology to meet the
information needs of participants during the informed consent process. The research team
need to keep enough time in discussing the participants’ concerns about the research, in
addition to the multimedia. The multimedia could in fact replace the first part of ‘traditional’
consent interview. It could be followed by an interview where the participants would still be
free to ask clarification questions. Thus, the overall acceptance and success of the tool will
ultimately depend on a well-balanced combination of the technology and human elements.
Although both quantitative and qualitative assessments adopted in our study consistently
revealed improvements in participants’ comprehension scores, caution is required in
interpreting these observations because our study targeted healthy volunteers who were not
enrolled in any study. The simulated trial situation might have over-estimated the
advantages of the multimedia tool and under-estimated other factors which would be present
in real life, e.g. the participants’ anxiety and haste to get enrolled. Nevertheless, increases in
participants’ comprehension scores over a one-week period were consistent with the design
of this study. The use of repeated measures design allowed the study participants to serve as
their own control. This improves the precision of the study by reducing the size of the error
variance.
Another limitation of our study may be due to the fact that it reflects the situation in The
Gambia, where local languages do not have written standardised forms. Consequently, we
suggest that the tool should be later tested and adapted in different sub-Saharan African
contexts.
Our study provides important information on the development and evaluation of a
multimedia strategy for improving comprehension in research informed consent to low
literacy individuals. Information shared on processes involved in the development will serve
as a useful guide for investigators in similar settings. Another study comparing the
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multimedia consent to the ‘conventional’ consent procedure among participants enrolled for
the parent trial is currently ongoing. We hope findings of the study will shed more lights on
the efficacy of multimedia in a real-life setting.
Conclusions
This study developed and evaluated a multimedia informed consent tool for improving the
informed consent procedure, and noteworthy comprehension, in low literacy participants in
The Gambia. We carried out an initial assessment of the strength of the tool and identified
areas for further research and improvement. This study represents an important step towards
institutionalising a context-specific informed consent tool. Future work is needed but there
was enthusiasm for this modality and potential to improve the informed consent process,
leading in turn to a better and more solid partnership between the community and the
clinical researchers in The Gambia.
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Table 1
Socio-demographic characteristics of the study participants.
Characteristics Frequency (%) N=42
Age group
18-25 years 4(9.5)
26-33 years 16(38.1)
34-41 years 13(31.0)
42-49 years 9(21.4)
Sex
Female 20(47.6)
Male 22(52.4)
Ethnicity
Mandinka 38(90.5)
Fula 4(9.5)
Highest level of education attained
Primary 2(4.8)
Secondary 2(4.8)
Arabic 29(69.0)
Vocational education 1(2.4)
No formal education 8(19.0)
Occupation
Artisan 7(16.7)
Farming 10 (23.8)
Housewife 17(40.5)
Schooling 1 (2.4)
Trading 7(16.7)
Area of domicile
Basse North 20(47.6)
Basse South 22(52.4)
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Table 2
Participants’ responses to questions on acceptability and ease of use of multimedia
informed consent tool.
1. Overall, how much do you like the following features of the multimedia
tool? Like (N=42) Dislike (N=42) I don’t know (N=42)
Colour 42(100.0) 0(0.0) 0(0.0)
Pictures 42(100.0) 0(0.0) 0(0.0)
Voices 42(100.0) 0(0.0) 0(0.0)
Duration 42(100.0) 0(0.0) 0(0.0)
2. Do you think the tool provide enough information about the study? Yes No I don’t know
42(100.0) 0(0.0) 0(0.0)
3. Overall, how comfortable are you with the information in the tool? Comfortable Very comfortable Not comfortable
30(71.4) 12(28.6) 0(0.0)
4. Overall, how easy or difficult did you find the Information provided In
the tool Easy Very easy Difficult
30(71.4) 12(28.6) 0(0.0)
5. Will you like to use it again? Yes No I don’t know
42(100.0) 0(0.0) 0(0.0)
6. Would you want future study information delivered through this tool? Yes No I don’t know
42(100.0) 0(0.0) 0(0.0)
7. Do you want any changes to the tool? Yes No I don’t know
4(9.5) 38(90.5) 0(0.0)
Table 2 shows that all participants liked the features of the multimedia tool, about 70% found it easy to follow and 10% suggested some changes to
the tool
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Table 3
Participants’ responses to questions on acceptability and ease of use of digitised
comprehension questionnaire (DICCQ).
1. Overall, how much do you like the following features of DICCQ? Like (N=42) Dislike (N=42) I don’t know (N=42)
Colour 42(100.0) 0(0.0) 0(0.0)
Pictures 42(100.0) 0(0.0) 0(0.0)
Voices 42(100.0) 0(0.0) 0(0.0)
Duration 39(92.9) 3(7.1) 0(0.0)
2. Overall, how easy or difficult did you find the questions provided In the
tool Easy Very easy Difficult
24(57.1) 18(42.9) 0(0.0)
3. Overall, how comfortable are you with the information in the tool? Comfortable Very comfortable Not comfortable
30(71.4) 11(26.2) 1(2.4)
4. Will you like to use it again? Yes No I don’t know
42(100.0) 0(0.0) 0(0.0)
5. Would you want future study questionnaires delivered through this
tool? Yes No I don’t know
42(100.0) 0(0.0) 0(0.0)
6. Do you want any changes to the tool? Yes No I don’t know
7(16.7) 35(83.3) 0(0.0)
Table 3 shows that majority of the participants liked the features of the audio questionnaire, about 60% found it easy to follow and 17% suggested
changes to the tool
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Table 4
Descriptive statistics of participants’ scores on the audio digitised comprehension
questionnaire (DICCQ).
Section A: Choose only one right answer Mean SD* Minimum Maximum
1. Have you been told that you can freely decide to take part in this study? 2.86 0.65 0 3
2 Have you been told you can withdraw from this study anytime? 2.74 0.83 0 3
3. During the study, will you know the drug you or your child is receiving? 2.86 0.52 1 3
4. If yes, describe or mention what the drug is doing? 2.95 1.10 1 5
5. During the study, will anyone not working with MRC know about your healthinformation? 2.29 1.23 0 3
6. Have you been given the name and phone number of the person to contact if you have
any questions about the study? 2.50 0.99 0 3
7. If yes, mention the name of the person? 2.07 1.30 0 3
8. Can your participation in the study be stopped without your consent? 1.49 1.49 0 3
9. Will you receive money for taking part in the study? 2.52 0.94 0 3
Section B: Answer the following questions by circling the right answer
10. How were participants divided into different groups in this study? 0.02 0.15 0 1
11. At what point can you leave the study? 2.02 1.41 0 3
12. What does it mean when you sign or thumbprint the study consent form? 2.93 0.46 0 3
13. How did you decide to participate in this study? 1.79 1.49 0 3
14. What will you receive as a reward for taking part in the study? 2.79 0.78 0 3
15. What will happen if you decide to stop taking part in this study? 2.71 0.89 0 3
Section C: You will need to circle more than one correct answers in this part
16. Which of the following describes why the primaquine study is being done? 2.95 1.01 2 4
17. Which procedures were you asked to take part in? 3.33 0.95 2 4
18. Which activities were you asked to complete? 2.76 0.98 2 4
19. Which describes the main benefits of taking part in the study? 3.04 1.01 2 4
Section D: In this section, you are requested to provide answers that are specific to the
study you are currently participating.
20. Please tell me what the researchers want to find out in the study? 2.92 0.78 0 5
21. How many times do you have to come to the clinic for a visit during the study? 3.17 2.17 0 5
22. Tell me what will be done during the study visits? 2.92 1.26 0 5
23. How are participant assigned into different groups this study? 0.88 1.13 0 3
24. What is the difference between taking part in this study and going to see a doctor fortreatment? 2.97 2.48 0 3
25. What are the possible unwanted effects of taking part in this study? 4.36 1.21 0 5
26. Why do you think some of the study participants were given different medicine? 2.98 2.48 0 3
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Table 5
Repeated measures analysis of variance of participants’ recall and understanding scores.
‘Recall’ scores (N=42) ‘Understanding’ scores (N=42)
1st visit 25.62±4.4 55.00±5.58
2nd visit 27.95±4.8 58.5952±7.06
Within-participant effects F-test=25.38P<0.001
F-test=31.61
P<0.001
Between-participant effects F-test=1588.91P<0.0001
F-test=3743.267
P<0.0001
Pairwise comparison of significance levels for the time difference
Mean time difference =2.33
S.E=0.463, P<0.0001
95% CI (1.398-3.269)
Mean time difference= 3.60
S.E=0.639, P<0.0001
95% CI (2.304-4.887)
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